Intravitreal Aflibercept Versus Photodynamic Therapy in Chinese Patients with Neovascular Age-Related Macular Degeneration: Outcomes of the SIGHT Study-Reference-Cited by-同舟云学术

Intravitreal Aflibercept Versus Photodynamic Therapy in Chinese Patients with Neovascular Age-Related Macular Degeneration: Outcomes of the SIGHT Study

Published:2017-07 Issue:6 Volume:33 Page:435-444
ISSN:1080-7683
Container-title:Journal of Ocular Pharmacology and Therapeutics
language:en
Short-container-title:Journal of Ocular Pharmacology and Therapeutics

Author:

Li Xiaoxin¹,Chen Youxin²,Zhang Junjun³,Xu Xun⁴,Zhang Feng⁵,Cheung Chui Ming Gemmy⁶,Yu Rui⁷,Kazmi Husain⁸,Sowade Olaf⁹,Zeitz Oliver⁹,on behalf of the SIGHT study group

Affiliation:

1. Department of Ophthalmology, People's Eye Center, Peking University People's Hospital, Xicheng District, Beijing, China.

2. Department of Ophthalmology, Peking Union Medical Colleague Hospital, Dongcheng District, Beijing, China.

3. Department of Ophthalmology, West China School of Medicine/West China Hospital, Sichuan University, Wuhou District, Chengdu, China.

4. Department of Ophthalmology, Shanghai General Hospital, Hongkou District, Shanghai, China.

5. Department of Ophthalmology, Beijing Tongren Hospital, CMU, Dongcheng District, Beijing, China.

6. Department of Ophthalmology, Singapore Eye Research Institute, Singapore, Singapore.

7. Department of Ophthalmology, Bayer US, Whippany, New York.

8. Ophthalmology, Regeneron Pharmaceuticals, Inc., Tarrytown, New York.

9. Development, Pharmaceuticals, Bayer AG, Berlin, Germany.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmacology,Ophthalmology

Link

http://www.liebertpub.com/doi/pdf/10.1089/jop.2016.0071

Reference14 articles.

1. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

2. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

3. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

4. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial;Ophthalmology and Therapy;2023-11-21

2. Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis;Journal of Clinical Medicine;2022-03-25

3. Comment on: Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study;American Journal of Ophthalmology;2020-01

4. Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis;Therapeutic Advances in Chronic Disease;2020-01

5. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration;Cochrane Database of Systematic Reviews;2019-03-04